留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

静脉血栓栓塞症抗凝新药物

叶炜 刘昌伟

叶炜, 刘昌伟. 静脉血栓栓塞症抗凝新药物[J]. 协和医学杂志, 2013, 4(1): 52-57. doi: 10.3969/j.issn.1674-9081.2013.01.012
引用本文: 叶炜, 刘昌伟. 静脉血栓栓塞症抗凝新药物[J]. 协和医学杂志, 2013, 4(1): 52-57. doi: 10.3969/j.issn.1674-9081.2013.01.012

静脉血栓栓塞症抗凝新药物

doi: 10.3969/j.issn.1674-9081.2013.01.012
基金项目: 

北京协和医院青年基金 (2010-174

详细信息
    通讯作者:

    刘昌伟 电话:010-69158332, E-mail:liucw@vip.sina.com

  • 中图分类号: R543.6;R453.9

  • 图  1  抗凝新药物作用靶点示意图

  • [1] Heit JA. The epidemiology of venous thromboembolism in the community[J]. Arterioscler Thromb Vasc Biol, 2008, 28:370-372. doi:  10.1161/ATVBAHA.108.162545
    [2] Schünemann HJ, Cook D, Guyatt G, et al.Methodology for antithrombotic and thrombolytic therapy guideline development:American College of Chest Physicians evidence-based clinical practice guidelines (8th ed)[J]. Chest, 2008, 133:113S-122S. doi:  10.1378/chest.08-0666
    [3] Guyatt GH, Eikelboom JW, Gould MK, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e185S-194S. http://www.onacademic.com/detail/journal_1000038942250310_d3e0.html
    [4] 吕厚山, 徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志, 1999, 19:155-156. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgkzz98199903008
    [5] 孙建行.创伤性下肢深静脉血栓形成的治疗探讨[J].中国中医骨伤科杂志, 2007, 15:6-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzygsk200704002
    [6] 中华医学会心血管病学分会肺血管病学组, 中国医师协会心血管内科医师分会.急性肺血栓栓塞症诊断治疗中国专家共识[J].中华内科杂志, 2010, 49:74-81. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201001026
    [7] 中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南(第二版)[J].中华外科杂志, 2012, 50:611-613. http://qikan.cqvip.com/Qikan/Article/Detail?id=1003027731
    [8] Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2009, 37:74-81. doi:  10.1124/dmd.108.023143
    [9] Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Ⅹa[J]. J Med Chem, 2007, 50:5339-5356. doi:  10.1021/jm070245n
    [10] Buller H, Deitchman D, Prins M, et al.Efficacy and safety of the oral direct factor Ⅹa inhibitor apixaban for symptoma-tic deep vein thrombosis:the Botticelli DVT dose-ranging study[J]. J Thromb Haemost, 2008, 6:1313-1318. doi:  10.1111/j.1538-7836.2008.03054.x
    [11] Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J]. N Engl J Med, 2009, 361:594-604. doi:  10.1056/NEJMoa0810773
    [12] Lassen MR, Raskob GE, Gallus A, et al. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2):a randomised double-blind trial[J]. Lancet, 2010, 375:807-815. doi:  10.1016/S0140-6736(09)62125-5
    [13] Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e278S-325S. http://cid.oxfordjournals.org/external-ref?access_num=10.1378/chest.11-2296&link_type=DOI
    [14] Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos, 2008, 36:386-399. doi:  10.1124/dmd.107.019083
    [15] Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:a randomised, double-blind, non-inferiority trial[J]. Lancet, 2007, 370:949-956. doi:  10.1016/S0140-6736(07)61445-7
    [16] Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:the RE-MODEL randomized trial[J]. J Thromb Haemost, 2007, 5:2178-2185. doi:  10.1111/j.1538-7836.2007.02748.x
    [17] Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery[J]. J Arthroplasty, 2009, 24:1-9. doi:  10.1016/S0883-5403(08)00834-6
    [18] Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J]. N Engl J Med, 2009, 361:2342-2352. http://gut.bmj.com/external-ref?access_num=10.1056/NEJMoa0906598&link_type=DOI
    [19] Schulman S, Kakkar AK, Schellong S, et al.A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER Ⅱ)[J]. Blood, 2011, 118:205.
    [20] Schulman S, Baanstra D, Eriksson H, et al.Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism[J]. J Thromb Haemost, 2011, 9:22. http://www.researchgate.net/publication/295663864_Dabigatran_vs_placebo_for_extended_maintenance_therapy_of_venous_thromboembolism
    [21] Kubitza D, Becka M, Wensing G, et al.Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Ⅹa inhibitor-after multiple dosing in healthy male subjects[J]. Eur J Clin Pharmacol, 2005, 61:873-880. doi:  10.1007/s00228-005-0043-5
    [22] Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med, 2008, 358:2765-2775. doi:  10.1056/NEJMoa0800374
    [23] Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind, randomised controlled trial[J]. Lancet, 2008, 372:31-39. doi:  10.1016/S0140-6736(08)60880-6
    [24] Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4):a randomised trial[J]. Lancet, 2009, 373:1673-1680. doi:  10.1016/S0140-6736(09)60734-0
    [25] Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med, 2008, 358:2776-2786. doi:  10.1056/NEJMoa076016
    [26] EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363:2499-2510. doi:  10.1056/NEJMoa1007903
    [27] EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].N Engl J Med, 2012, 366:1287-1297. doi:  10.1056/NEJMoa1113572
    [28] Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism:the continued treatment study (EINSTEIN-extension study)[J]. Expert Rev Cardiovasc Ther, 2011, 9:841-844. doi:  10.1586/erc.11.62
    [29] Weitz JI, Bates SM. New anticoagulants[J]. J Thromb Haemost, 2005, 3:1843-1853. doi:  10.1111/j.1538-7836.2005.01374.x
    [30] Samama MM, Le Flem L, Guinet C, et al. Comparative responses of some clotting assays to fondaparinux, dabigatran and rivaroxaban. 20th international congress on thrombosis, June 25-28, 2008[C]. Athens, Greece: [s.n.], 2008.
  • 加载中
图(1)
计量
  • 文章访问数:  157
  • HTML全文浏览量:  54
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-09-07
  • 刊出日期:  2013-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!